Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.
Yufang LiuXiaomei ZhangSanbao ChaiXin ZhaoXiantong ZouPublished in: Journal of diabetes research (2019)
GLP-1 receptor agonists can be used without safety concerns related to malignant neoplasia in patients with type 2 diabetes.
Keyphrases